Jinhyun Cho

Incheon, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Correction: Evidence‑based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions.

Correction: Evidence‑based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions.

Journal: Blood research

Published: April 08, 2025

Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions.

Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions.

Journal: Blood research

Published: October 02, 2024

Relative efficacy of systemic treatments for patients with relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis according to 17p deletion/TP53 mutations.

Relative efficacy of systemic treatments for patients with relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis according to 17p deletion/TP53 mutations.

Journal: Blood research

Published: August 06, 2024

The Risk and Reversibility of Osimertinib-Related Cardiotoxicity in a Real-World Population.

The Risk and Reversibility of Osimertinib-Related Cardiotoxicity in a Real-World Population.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: August 05, 2024

CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis.

CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis.

Journal: Blood

Published: November 28, 2023

Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis.

Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis.

Journal: Cancer research and treatment

Published: December 26, 2022

A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21).

A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21).

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: May 31, 2022

Association of Smoking Status with Efficacy of First-line Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancers: A Systematic Review and Meta-analysis.

Association of Smoking Status with Efficacy of First-line Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancers: A Systematic Review and Meta-analysis.

Journal: Journal of Cancer

Published: July 26, 2021

Comparison of first-line treatments of peripheral T-cell lymphoma according to regimen: A systematic review and meta-analysis.

Comparison of first-line treatments of peripheral T-cell lymphoma according to regimen: A systematic review and meta-analysis.

Journal: Hematological oncology

Published: June 30, 2021

Correction: The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors.

Correction: The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 16, 2020

Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs.

Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs.

Journal: Immune network

Published: August 12, 2020

MEK blockade overcomes the limited activity of palbociclib in head and neck cancer.

MEK blockade overcomes the limited activity of palbociclib in head and neck cancer.

Journal: Translational oncology

Published: May 17, 2020

Showing 1-12 of 30

Last Updated: 09/26/2026